Many patients with prostate cancer experience severe levels of depression, which can negatively affect their treatment and disease course. Some prostate cancer treatments can increase the severity of a patient’s depression, for example, by increasing anhedonia and erectile dysfunction. Depression is often thought of as a unitary phenomenon, but multiple subtypes can be distinguished. This variety of manifestations challenges the successful application of universal antidepressant treatment options and argues for a multi-symptom assessment process that considers a patient’s disease burden and their particular form of depression. Inclusion of screening and detailed diagnosis of depression can be argued to be part of good practice, and clinicians are urged to consider when and how this might be accomplished within their urological practice.
Rates of depression among patients with prostate cancer are higher than in the general male population, principally owing to the uncertainty of treatment outcomes.
Depression can interfere with treatment outcomes, worsen a patient’s disease burden and increases treatment costs because of an increased risk of emergency room visits, outpatient services and hospitalizations.
Causal factors for depression include treatment modalities and adverse effects, genetic and biological factors, and psychological problems.
Associated factors for depression include patient sexuality, self-belief about coping with treatment, personality type and relationship status.
Depression is a heterogeneous disease and multiple subtypes can be distinguished, requiring targeted assessment strategies that focus on depression subtypes as well as overall depressive status.
Treatments for depression in men with prostate cancer include medication, psychotherapy, exercise and providing information, depending on the type of depression with which the patient presents.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Cancer Causes & Control Open Access 09 September 2022
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).
International Agency for Research on Cancer & World Health Organization. Cancer Today. IARC https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf (2018).
Wang, G. et al. Genetics and biology of prostate cancer. Genes. Dev. 32, 1105–1140 (2018).
Di Nunno, V. et al. Systemic treatment for metastatic hormone sensitive prostate cancer: a comprehensive meta-analysis evaluating efficacy and safety in specific sub-groups of patients. Clin. Drug Investig. 40, 211–226 (2020).
Watts, S. et al. Depression and anxiety in prostate cancer: a systematic review and meta-analysis of prevalence rates. BMJ Open 4, e003901 (2014).
Guo, Z. et al. Incidence and risk factors of suicide after a prostate cancer diagnosis: a meta-analysis of observational studies. Prostate Cancer Prostatic Dis. 21, 499–508 (2018).
Jayadevappa, R. et al. The burden of depression in prostate cancer. Psychooncology 21, 1338–1345 (2012).
Cheng, Y. et al. Depression induced neuropeptide Y secretion promotes prostate cancer growth by recruiting myeloid cells. Clin. Cancer Res. 25, 2621–2632 (2019).
Rush, A. et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* report. Am. J. Psychiatry 163, 1905–1917 (2006).
Liu, Q. et al. Changes in the global burden of depression from 1990 to 2017: findings from the global burden of disease study. J. Psychiatr. Res. 126, 134–140 (2020).
World Health Organization. “Depression: let’s talk” says WHO, as depression tops list of causes of ill health (WHO, 2017).
Moussavi, S. et al. Depression, chronic diseases, and decrements in health; results from the World Health Surveys. Lancet 370, 851–858 (2007).
Langa, K. M. et al. Extent cost of informal caregiving for older Americans with symptoms of depression. Am. J. Psychiatry 161, 857–863 (2004).
Mykletun, A. et al. Levels of anxiety and depression as predictors of mortality: the HUNT study. Br. J. Psychiatry 195, 118–125 (2009).
Walker, E., McGee, R. & Druss, B. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry 72, 334–341 (2015).
Patel, V. et al. Addressing the burden of mental, neurological, and substance use disorders: key messages from disease control priorities, 3rd edition. Lancet 387, 1672–1685 (2016).
Thornicroft, G. et al. Undertreatment of people with major deperssive disorder in 21 countries. Br. J. Psychiatry 210, 119–124 (2017).
Caruso, R. et al. Depressive spectrum disorders in cancer: prevalence, risk factors, and screening for depression: a critical review. Acta Oncol. 56, 146–155 (2017).
Krebber, A. et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. Psychooncology 23, 121–130 (2014).
Bennet, G. & Badger, T. A. Depression in men with prostate cancer. Oncol. Nurs. Forum 32, 545–556 (2005).
Sharpley, C., Bitsika, V. & Christie, D. Psychological distress among prostate cancer patients: fact or fiction? Clin. Med. Oncol. 2, 563–572 (2008).
Steele, C. et al. Prostate cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 study. Cancer 123, 5160–5177 (2017).
Sharpley, C. & Christie, D. An analysis of the psychometric structure and frequency of anxiety and depression in Australian men with prostate cancer. Psychooncology 16, 660–667 (2007).
Zung, W. A self-rating depression scale. Arch. Gen. Psychiatry 12, 63–70 (1965).
Sharpley, C. et al. Total depression and subtypes in prostate cancer survivors 10 years after treatment. Eur. J. Cancer Care 26, e12630 (2017).
Chambers, S. et al. Trajectories of quality of life, life satisfaction, and psychological adjustment after prostate cancer. Psychooncology 26, 1576–1585 (2017).
Medical Outcomes Trust & QualityMetric Incorporated. SF-36 Health Survey (MOTaQM, 2003).
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 5th edn (APA, 2013).
World Health Organization. The ICD-10 classification of mental and behavioral disorders: diagnostic criteria for research (WHO, 1996).
Miaskowski, C. et al. Predictors of the trajectories of self-reported sleep disturbance in men with prostate cancer during and following radiation therapy. Sleep 34, 171–179 (2011).
Thorsteinsdottir, T. et al. Thinking about one’s own death after prostate-cancer diagnosis. Supportive Care Cancer 26, 1665–1673 (2018).
Robson, A. et al. The risk of suicide in cancer patients: a review of the literature. Psychooncology 19, 1250–1258 (2010).
Conwell, Y., Duberstein, P. & Caine, E. Risk factors for suicide in later life. Biol. Psychiatry 52, 193–204 (2002).
Sharpley, C., Christie, D. & Bitsika, V. Do hormone treatments for prostate cancer cause anxiety and depression? Int. J. Clin. Oncol. 19, 523–530 (2014).
Smith, D. et al. Increased risk of suicide in New South Wales men with prostate cancer: analysis of linked population-wide data. PLoS One 13, e0198679 (2018).
Caldwell, T., Jorm, A. & Dear, K. Suicide and mental health in rural, remote and metropolitan areas in Australia. Med. J. Aust. 181, S10–S14. (2004).
Sforzini, L. et al. Inflammation in cancer and depression: a starring role for the kynurenine pathway. Psychopharmacology 236, 2997–3011 (2019).
Helgason, A. et al. ‘Potency’: the validation of information from a self-administered questionnaire using objective measurements of night-time erections and test-retest reliability. Br. J. Urol. 81, 135–141 (1998).
Helgason, A. R. et al. Waning sexual function — the most important disease-specific distress for patients with prostate cancer. Br. J. Cancer 73, 1417–1421 (1996).
Parker, P. et al. Relationship between illness uncertainty, anxiety, fear of progression and quality of life in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int. 117, 469–477 (2016).
Sharpley, C., Bitsika, V. & Christie, D. “The worst thing was…”: prostate cancer patients’ evaluations of their diagnosis and treatment experiences. Am. J. Mens Health 12, 1503–1509 (2018).
Sharp, L. et al. The psychological impact of prostate biopsy: prevalence and predictors of procedure-related distress. Psychooncology 27, 500–507 (2018).
Smith, A. et al. Robot or radiation? A qualitative study of the decision support needs of men with localised prostate cancer choosing between robotic prostatactomy and radiotherapy treatment. Patient Educ. Couns. 102, 1364–1372 (2019).
Perry, L. et al. Understanding the distressed prostate cancer patient: role of personality. Psychooncology 27, 810–816 (2018).
Oba, A. et al. Psychological distress in men with prostate cancer and their partners before and after cancer diagnosis: a longitudinal study. Jpn. J. Clin. Oncol. 47, 735–742 (2017).
Orom, H., Underwood, W. & Biddle, C. Emotional distress increases the likelihood of undergoing surgery among men with localized prostate cancer. J. Urol. 197, 350–355 (2017).
Ussher, J. et al. Health-related quality of life, psychological distress, and sexual changes following prostate cancer: a comparison of gay and bisexual men with heterosexual men. J. Sex. Med. 13, 425–434 (2016).
Rosser, B. et al. The sexual functioning of gay and bisexual men following prostate cancer treatment: results from the restore study. Arch. Sex. Behav. 49, 1589–1600 (2020).
Orom, H. et al. Factors associated with emotional distress in newly diagnosed prostate cancer patients. Psychooncology 24, 1416–1422 (2015).
Pachankis, J. Uncovering clinical principles and techniques to address minority stress, mental health, and related health risks among gay and bisexual men. Clin. Psychol. Sci. Pract. 21, 313–330 (2014).
Flett, G., Hewitt, P. & Dyck, D. Self-oriented perfectionism, neuroticism and anxiety. Pers. Individ. Dif. 10, 731–735 (1989).
Benetti, C. & Kambouropoulos, N. Affect-regulated indirect effects of trait anxiety and trait resilience on self-esteem. Pers. Individ. Dif. 41, 341–352 (2006).
Hedden, L. et al. Evaluating an educational intervention to alleviate distress amongst men with newly diagnosed prostate cancer and their partners. BJU Int. 120, E21–E29 (2017).
Lehto, U.-S., Aromaa, A. & Tammela, T. Experiences and psychological distress of spouses of prostate cancer patients at time of diagnosis and primary treatment. Eur. J. Cancer Care 27, e12729 (2018).
Donovan, J. et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N. Engl. J. Med. 375, 1425–1437 (2016).
Zigmond, A. & Snaith, R. The hospital anxiety and depression scale. Acta Psychiatr. Scand. 67, 361–370 (1983).
Dinh, K. et al. Association of androgen deprivation therapy with depression in localized prostate cancer. J. Clin. Oncol. 34, 1905–1912 (2016).
Sharp, L. et al. Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: results from the PiCTure study. Psychooncology 25, 282–291 (2016).
Chen, Y.-Z. et al. The relationship between androgen deprivation therapy and depression symptoms in patients with prostate cancer. Aging Male 16, 1–6 (2019).
Thomas, H. et al. Association between androgen deprivation therapy and patient-reported depression in men with recurrent prostate cancer. Clin. Genitourin. Cancer 16, 313–317 (2018).
Zhang, Z. et al. Depressive symptoms are found to be potential adverse effects of androgen deprivation therapy in older prostate cancer patients: a 15-month prospective, observational study. Psychooncology 26, 2238–2244 (2017).
Sharpley, C. et al. Trajectories of total depression and depressive symptoms in prostate cancer patients receiving six months of hormone therapy. Psychooncology 26, 60–66 (2017).
Carter, G. et al. Wellbeing during Active Surveillance for localised prostate cancer: a systematic review of psychological morbidity and quality of life. Cancer Treat. Rev. 41, 46–60 (2015).
Ruane-McAteer, E. et al. Active surveillance for favorable-risk prostate cancer: is there a greater psychological impact than previously thought? A systematic, mixed studies literature review. Psychooncology 26, 1411–1421 (2017).
Dickey, S. & Grayson, C. The quality of life among men receiving active surveillance for prostate cancer: an integrative review. Healthcare 7, 14 (2019).
Culverhouse, R. et al. Collaborative meta-analysis finds no evidence of a strong interaction between stress and 5-HTTLPR genotype contributing to the development of depression. Mol. Psychiatry 23, 133 (2017).
Lesch, K. P. Gene-environment interaction and the genetics of depression. J. Psychiatry Neurosci. 29, 174–184 (2004).
Harmer, C. Serotonin and emotional processing: does it help explain antidepressant drug action? Neuropharmacology 55, 1023–1028 (2008).
Hayden, E. et al. Early-emerging cognitive vulnerability to depression and the serotonin transporter promoter region polymorphism. J. Affect. Disord. 107, 227–230 (2008).
Strawbridge, R., Young, A. & Cleare, A. Biomarkers for depression: recent insights, current challenges and future prospects. Neuropsychiatr. Dis. Treat. 13, 1245–1262 (2017).
Papakostas, G. et al. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol. Psychiatry 18, 332–339 (2013).
Sharpley, C. et al. Comparing a genetic and a psychological factor as correlates of anxiety, depression, and chronic stress in men with prostate cancer. Support. Care Cancer 26, 3195–3200 (2018).
Sharpley, C. et al. Does psychological resilience buffer against the link between the 5-HTTLPR polymorphism and depression following stress? Physiol. Behav. 180, 53–59 (2017).
Sharpley, C. et al. Variability over time-since-diagnosis in the protective effect of psychological resilience against depression in Australian prostate cancer patients: implications for patient treatment models. Am. J. Mens Health 7, 414–422 (2013).
Luthar, S. & Cicchetti, D. The construct of resilience: implications for interventions and social policies. Dev. Psychopathol. 12, 857–885 (2000).
Charney, D. S. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Focus 2, 368–391 (2004).
Cicchetti, D. & Blender, J. A. A multiple-levels-of-analysis perspective on resilience. Ann. NY Acad. Sci. 1094, 248–258 (2006).
Haglund, M. E. M. et al. Psychobiological mechanisms of resilience: relevance to prevention and treatment of stress-related psychopathology. Dev. Psychopathol. 19, 889–920 (2007).
Sharpley, C. et al. Does resilience “buffer” against depression in prostate cancer patients? A multi-site replication. Eur. J. Cancer Care 23, 545–552 (2014).
Palmer, M. et al. Incontinence after prostatectomy: coping with incontinence after prostate cancer surgery. Oncol. Nurs. Forum 30, 229–238 (2003).
Zorn, B. et al. Urinary incontinence and depression. J. Urol. 162, 82–84 (1999).
Sharpley, C. et al. Psychological resilience aspects that mediate the depressive effects of urinary incontinence in prostate cancer survivors 10 years after treatment with radiation and hormone ablation. J. Psychosoc. Oncol. 35, 438–450 (2017).
Prasad, S. et al. Effects of depression on diagnosis, treatment, and mortality of men with clinically localized prostate cancer. J. Clin. Oncol. 32, 2471–2478 (2014).
Pompe, R., Kruger, A. & Preisser, F. et al. The impact of anxiety and depression on surgical and functional outcomes in patients who underwent radical prostatectomy. Eur. Urol. Focus https://doi.org/10.1016/j.euf.2018.12.008 (2018).
Safdieh, J., Scwartz, D. & Rineer, J. Does the presence of a major psychiatric disorder affect tolerance and outcomes in men with prostate cancer receiving radiation therapy? Am. J. Mens Health 11, 5–12 (2017).
Sharpley, C. & Bitsika, V. Differences in neurobiological pathways of four “clinical content” subtypes of depression. Behav. Brain Res. 256, 368–376 (2013).
Sharpley, C. & Bitsika, V. Validity, reliability and prevalence of four ‘Clinical Content’ subtypes of depression. Behav. Brain Res. 259, 9–15 (2014).
Judd, L. et al. Subsyndromal symptomatic depression: a new mood disorder? J. Clin. Psychiatry 55, 18–28 (1994).
Judd, L. et al. Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am. J. Psychiatry 163, 1411–1417 (1996).
Lyness, J. et al. Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann. Intern. Med. 144, 496–504 (2006).
Chopra, M. et al. Importance of subsyndromal symptoms of depression in elderly patients. Am. J. Geriatr. Psychiatry 13, 597–606 (2005).
Lyness, J. et al. The clinical significance of subsyndromal depression in older primary care patients. Am. J. Geriatr. Psychiatry 15, 214–223 (2007).
Sharpley, C., Bitsika, V. & Christie, D. Incidence, structure and interrelationships of subsyndromal depression symptomatology in prostate cancer patients. Ger. J. Psychiatry 16, 95–102 (2013).
Ostergaard, S., Jensen, S. & Bech, P. The heterogeneity of the depressive syndrome: when numbers get serious. Acta Psychiatr. Scand. 124, 495–496 (2011).
Beijers, L. et al. Data-driven biological subtypes of depression: systematic review of biological approaches to depression subtyping. Mol. Psychiatry 24, 888–900 (2019).
Sharpley, C., Bitsika, V. & Christie, D. The incidence and causes of different subtypes of depression in prostate cancer patients: implications for cancer care. Eur. J. Cancer Care 22, 815–823 (2013).
Fried, E. & Nesse, R. Depression is not a consistent syndrome: an investigation of unique symptom patterns in the STAR*D study. J. Affect. Disord. 172, 96–102 (2015).
Fried, E. & Nesse, R. Depression sum-scores don’t add up: why analyzing specific depression symptoms is essential. BMC Med. 13, 72 (2015).
Innamorati, M. et al. Psychometric properties of the Gotland scale for depression in Italian psychiatric patients and its utility in the prediction of suicide risk. J. Affect. Disord. 132, 99–103 (2011).
Maria Möller-Leimkühler, A. et al. Is there evidence for a male depressive syndrome in inpatients with major depression? J. Affect. Disord. 80, 87–93 (2004).
Möller Leimkühler, A., Heller, J. & Paulus, N. Subjective well-being and ‘male depression’ in male adolescents. J. Affect. Disord. 98, 65–72 (2007).
Rutz, W. et al. Prevention of male suicides: lessons from Gotland study. Lancet 345, 524 (1995).
Wålinder, J. & Rutz, W. Male depression and suicide. Int. Clin. Psychopharmacol. 16, S21–S24 (2001).
Zierau, F. et al. The Gotland male depression scale: a validity scale in patients with alcohol use disorder. Nordic J. Psychiatry 56, 265–271 (2002).
Winkler, D., Pjrek, E. & Kasper, S. Anger attacks in depression — evidence for a male depressive syndrome. Psychother. Psychosom. 74, 303–307 (2005).
Sharpley, C., Bitsika, V. & Christie, D. Diagnosing ‘Male Depression’ in prostate cancer patients: the next step in translational psycho-oncology interventions? Psychooncology 23, 1042–1048 (2014).
Zeckhauser, R. & Shepard, D. Where now for saving lives? Law Contemp. Probl. 40, 5–45 (1976).
Murray, C. Quantifying the burden of disease: the technical basis for disability-adjusted life years. Bull. World Health Organ. 72, 429–445 (1994).
IsHak, W. et al. Development and validation of the individual burden of illness index for major depressive disorder (IBI-D). Adm. Policy Ment. Health 40, 76–86 (2011).
Cohen, R., Greenberg, J. & IsHak, W. Incorporating multidimensional patient-recorded outcomes of symptoms of severity, functioning, and quality of life in the individual burden of illness index for depression to measure treatment impact and recovery in MDD. JAMA Psychiatry 70, 343–350 (2013).
Kroenke, K., Spitzer, R. & Williams, J. The PHQ-9: validity of a brief depression severity measure. J. Gen. Intern. Med. 16, 606–613 (2001).
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders 4th edn (APA, 2000).
van Andel, G. et al. An international field study of the EORTC QLQ-PR25: a questionnaire for assessing the health-related quality of life of patients with prostate cancer. Eur. J. Cancer 44, 2418–2424 (2008).
Sharpley, C., Bitsika, V. & Christie, D. Measuring individual burden of illness for depression in prostate cancer patients. Psychooncology 23, 886–891 (2014).
Lovibond, S. & Lovibond, P. Manual for the Depression Anxiety Stress Scales 2nd edn (Psychology Foundation of Australia, 1995).
Cutillo, A. et al. The distress thermometer: cutoff points and clinical use. Oncol. Nurs. Forum 44, 329–336 (2017).
Skoogh, J. et al. “A no means no”; measuring depression using a single-item question versus hospital anxiety and depression scale (HADS-D). Ann. Oncol. 21, 1905–1909 (2010).
Wallace, M., Frank, E. & Kraemer, H. A novel approach for developing and interpreting treatment moderator profiles in randomized clinical trials. JAMA Psychiatry 70, 1241–1247 (2013).
Bill-Axelson, A. et al. Psychiatric treatment in men with prostate cancer — results from a nation-wide, population-based cohort study from PCBaSe Sweden. Eur. J. Cancer 47, 2195–2201 (2011).
Tamim, H. et al. Antidepressants and risk of prostate cancer: a nested case–control study. Prostate Cancer Prostatic Dis. 11, 53 (2007).
Lorne, J. et al. Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res. 52, 3796–3800 (1992).
Chien, C.-H. et al. The effects of psychosocial strategies on anxiety and depresssion of pateints diagnosed with prostate cancer: a systematic review. Int. J. Nurs. Stud. 51, 28–38 (2014).
Newby, T. et al. Interventions that may reduce depressive symptoms among prostate cancer patients: a systematic review and meta-analysis. Psychooncology 24, 1686–1693 (2015).
Vartolomei, L., Shariat, S. & Vartolomei, M. Psychotherapeutic interventions targeting prostate cancer patients: a systematic review of the literature. Eur. Urol. Oncol. 1, 283–291 (2018).
Crawford-Williams, F. et al. Interventions for prostate cancer survivorship: a systematic review of reviews. Psychooncology 27, 2339–2348 (2018).
Naccarato, A. et al. Psychotherapy and phosphodiesterase-5 inhibitor in early rehabilitation after radical prostatectomy: a prospective randomised controlled trial. Andrologia 48, 1183–1187 (2016).
Penedo, F. et al. A randomized clinical trial of group-based cognitive-behavioral stress management in localized prostate cancer: development of stress management skills improves quality of life and benefit-finding. Ann. Behav. Med. 31, 261–270 (2006).
Collins, A. et al. Cognitive existential couple therapy for newly diagnosed prostate cancer patients and their partners: a descriptive pilot study. Psychooncology 22, 465–469 (2013).
Forbes, C. C. et al. A systematic review of the feasibility, acceptability, and efficacy of online supportive care interventions targeting men with a history of prostate cancer. J. Cancer Surviv. 13, 75–96 (2019).
Christie, D. & Sharpley, C. Depression and prostate cancer – why do they show up together? Nat. Rev. Urol. 11, 547–548 (2014).
Shoag, J. et al. Decline in prostate cancer screening by primary care physicians: an analysis of trends in the use of digital rectal examination and prostate specific antigen testing. J. Urol. 196, 1047–1052 (2016).
Fenton, J. et al. Prostate-specific antigen-based screening for prostate cancer: a systematic evidence review for the U.S. Preventive Services Task Force. Evidence synthesis no. 154 (Agency for Healthcare Research and Quality, 2018).
Ilic, D. et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ 362, k3519 (2018).
Mahar, P. et al. Prostate specific antigen — useful screening tool or potential liability? Aust. Fam. Physician 39, 598–600 (2010).
Bolla, M. & Mirnoff, R. Prostate cancer: on the road to progress. Asian J. Urol. 6, 123–124 (2019).
Grivas, N. et al. Ultrasensitive prostate-specific antigen level as a predictor of biochemical progression after robot-assisted radical prostatectomy: towards risk adapted follow-up. J. Clin. Lab. Anal. 33, e22693 (2019).
Perera, M. et al. Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer — updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur. Urol. 7, 403–417 (2020).
Daly, T. Evolution of definitive external beam radiation therapy in the treatment of prostate cancer. World J. Urol. 38, 565–591 (2020).
Chambers, S. et al. The validity of the distress thermometer in prostate cancer populations. Psychooncology 23, 195–203 (2014).
van der Donk, L. et al. Reasons for low uptake of a psychological intervention offered to cancer survivors with elevated depressive symptoms. Psychooncology 28, 830–838 (2019).
Hamdy, F. et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N. Engl. J. Med. 375, 1415–1424 (2016).
Costello, A. Considering the role of radical prostatectomy in 21st century prostate cancer care. Nat. Rev. Urol. 17, 177–188 (2020).
Beckta, J., Nosrati, J. & Yu, J. Moderate hypofractionation and stereotactic body radiation therapy in the treatment of prostate cancer. Urol. Oncol. 19, S1078–1439. (2019).
Mahal, B. et al. High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy? Ann. Oncol. 26, 1390–1395 (2015).
Duchesne, G. et al. Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial. Lancet Oncol. 17, 727–737 (2016).
Challapalli, A. et al. Evaluating the prevalence and predictive factors of vasomotor and psychological symptoms in prostate cancer patients receiving hormonal therapy: results from a single institution experience. Clin. Transl. Radiat. Oncol. 10, 29–35 (2018).
Pagliuca, M. et al. The evolving systemic treatment landscape for patients with advanced prostate cancer. Drugs 79, 381–400 (2019).
Kretschmer, A. et al. Health-related quality of life in patients with advanced prostate cancer: a systematic review. Eur. Urol. Focus https://doi.org/10.1016/j.euf.2020.01.017 (2020).
Nuhn, P. et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur. Urol. 75, 88–99 (2019).
Huber, J. et al. The effect of an online support group on patients' treatment decisions for localized prostatecancer: an online survey. Urol. Oncol. 35, 37.e19–37.e28 (2017).
Tablazon, I. et al. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: results from the shared equal access regional cancer hospital (SEARCH) database. Cancer 125, 4003–4010 (2019).
Beck, A. et al. An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561–571 (1961).
Radloff, L. S. The CES-D scale: a self-report depression scale for research in the general population. Appl. Psychol. Meas. 1, 385–401 (1977).
The authors declare no competing interests.
Peer review information
Nature Reviews Urology thanks G. Steineck, T. Hartung and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sharpley, C.F., Christie, D.R.H. & Bitsika, V. Depression and prostate cancer: implications for urologists and oncologists. Nat Rev Urol 17, 571–585 (2020). https://doi.org/10.1038/s41585-020-0354-4
This article is cited by
Cancer Causes & Control (2022)